Now that hematological oncologists have an arsenal of novel single agents, the natural next step is to determine the best combinations of these agetns, both with one another and with standard chemotherapeutics. In this interview, Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discusses advancements in chronic lymphocytic leukemia (CLL) therapy, particularly novel combinations, which have shown clinical promise. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA,
ASH 2017: CLL combination therapy highlights
